FDA 21 CFR Part 11 &amp; E-Signature Compliance Guides

Electronic Signatures for CDMOs: Part 11

Learn how Part 11 applies when sponsors and CDMOs share batch-record signatures, audit-trail review, release decisions, and quality agreements.

July 20, 20268 min read

CIOMS XIV AI Pharmacovigilance Framework: Mapping to 21 CFR Part 11 Attribution and Audit Trails

CIOMS Working Group XIV's AI pharmacovigilance framework rests on principles 21 CFR Part 11 already regulates. Here's how attribution and audit trail requirements carry over to AI-assisted signal detection.

July 13, 202610 min read

IRB Electronic Signature Requirements: What Part 11 Demands for Approval Letters

IRB and ethics committee records are subject to FDA Part 11 the moment they go electronic. This guide covers approval letter signatures, continuing review timing, member vote attribution, and common gaps in electronic IRB signature architecture.

July 7, 20268 min read

GMP Batch Release E-Signatures: The QA Release Sign-Off Workflow Under Part 11

Batch disposition is the highest-stakes signature event in GMP manufacturing. Here is the QA release sign-off workflow Part 11 and EU GMP Annex 11 both require.

June 30, 202612 min read

eTMF E-Signature Requirements: FDA Part 11, ICH E6(R3), and the Four Compliance Gaps

eTMF systems fall under FDA Part 11 because predicate rules require the TMF. Here are the four e-signature controls most often deficient in eTMF platforms.

June 29, 202613 min read

EU GMP Annex 22: AI Governance in GxP Systems — What Pharma Needs to Know

EMA's EU GMP Annex 22 governs AI in GxP environments: audit trail attribution, algorithm versioning, and human oversight. Here's what it requires.

June 27, 202611 min read

Informed Consent E-Signatures: FDA Part 11 Requirements

Electronic signatures on informed consent forms must satisfy both 21 CFR Part 50 and 21 CFR Part 11. This guide covers what the audit trail must capture for each consent event, re-consent workflows, IRB qualification questions, and the three most common 483 findings at investigator sites using electronic consent.

June 22, 20269 min read

21 CFR Part 11 Applicability Assessment: Predicate Rules and When Part 11 Applies

Part 11 applies only when a predicate rule requires a record kept electronically. Here is the two-part test and the three errors FDA inspectors find most.

June 21, 202611 min read

EU GMP Annex 11 Clause 3 Supplier Qualification: What Pharma Must Document Before Deployment

EU GMP Annex 11 Clause 3 requires a formal supplier qualification assessment before deploying any e-signature platform. This guide covers the six assessment elements, what documentation to request from vendors, and how to structure the assessment report for EU GMP audit readiness.

June 15, 202610 min read

Remote Monitoring Visits and Electronic Records: What ICH E6(R3) Requires for E-Signatures

ICH E6(R3) recognizes remote monitoring as GCP-compliant, but the Part 11 e-signature obligations for visit reports and delegation logs are unchanged. Here is what still applies.

June 15, 202613 min read

Company

Certivo is Now Klyverity

Certivo is now Klyverity. Same company, same team, same FDA 21 CFR Part 11 platform. Your account, data, signed records, and agreements all carry over.

June 12, 20264 min read

Part 11 Audit Trail Review SOP: Required Frequency and Elements

How often must Part 11 audit trails be reviewed, and what must the SOP say? Frequency by predicate rule, the six required SOP elements, and top FDA findings.

June 8, 202613 min read

21 CFR Part 11 vs EU GMP Annex 11: Side-by-Side Compliance Guide (2026)

FDA Part 11 and EU GMP Annex 11 share a common foundation but diverge on audit trail scope, supplier qualification, and periodic review. Here is the comparison.

June 6, 202614 min read

21 CFR Part 11 Audit Trail Requirements: What Your E-Signature System Must Log

Part 11 Section 11.10(e) requires secure, time-stamped audit trails. Here are the seven data elements every entry must capture and the gaps inspectors find.

June 1, 202613 min read

EU GMP Annex 11 2025 Draft: Electronic Signature Changes and MFA Requirement

The EMA's 2025 consultation draft of EU GMP Annex 11 makes multi-factor authentication explicitly mandatory for electronic signatures in GxP systems — the most significant update since the 2011 publication. Updated June 2026: finalization window now active, Annex 22 companion document for AI governance in development alongside it. Covers Clause 12.1 MFA requirement, Clause 9 expanded audit trail scope, Clause 16 AI attribution, how the draft compares to FDA Part 11 Section 11.200(a), and preparation steps before finalization.

May 23, 202612 min read

GxP Electronic Records: What FDA, EMA, and ICH Regulations Actually Require in 2026

GxP compliance spans four regulatory frameworks with different text and enforcement. Here's what Part 11, Annex 11, and ICH E6(R3) actually require.

May 20, 202614 min read

Electronic Signatures for Clinical Trials: Site Coordinator, Sponsor, and CRO Responsibilities

Part 11 e-signature duties split three ways in a clinical trial. Here is exactly what sponsors, CROs, and site coordinators are each on the hook for.

May 18, 202614 min read

GxP Compliant Electronic Signatures: What the Regulations Require and How to Select a Platform

"GxP compliant" is a claim, not a certification. A 10-question technical checklist for verifying a platform actually meets GMP, GLP, and GCP e-signature rules.

May 17, 202613 min read

HIPAA and 21 CFR Part 11: Dual Compliance for Healthcare Research

Healthcare research sites face simultaneous obligations under HIPAA and 21 CFR Part 11. Updated May 2026 to cover the March 2026 CMS final rule establishing the first HIPAA-adopted standard for electronic signatures in claims attachments — and what it means for organizations that must satisfy both federal frameworks at once. Covers the BAA requirement, two-component authentication at signing, signature meaning, non-repudiation letter obligations, and dual-compliance vendor selection.

May 11, 202612 min read

21 CFR Part 11 for Small Clinical Research Sites: What Site Coordinators Need to Know

Small investigator sites face the same Part 11 obligations as large sponsors, with fewer resources. Here's the practical three-SOP framework.

May 9, 202611 min read

FDA Part 11 Non-Repudiation Letter: What It Is, How to Write It, and Where to Submit

FDA requires written certification that your electronic signatures are legally binding. Here is who must submit one, what it must say, and where.

May 6, 202611 min read

ALCOA++ Data Integrity: Understanding the Tenth Principle for Pharmaceutical Audit Trails

ALCOA++ adds a tenth principle, Traceable, to ALCOA+. Learn what it requires for audit trail software and how to meet both FDA and EU expectations.

May 4, 202612 min read

Electronic Signature SOPs: What FDA Part 11 Requires and How to Write Them

FDA 21 CFR Part 11 Section 11.10(j) explicitly requires written policies holding individuals accountable for their electronic signatures. This guide covers the six SOPs every Part 11 system needs, what FDA investigators check during SOP audits, and how to structure each procedure.

May 3, 202613 min read

April 27, 202612 min read

21 CFR Part 11 Electronic Signature Validation: IQ OQ PQ Step-by-Step Guide

A practical guide to IQ, OQ, and PQ validation for 21 CFR Part 11 e-signature systems, including CSA's risk-based approach, specific test cases for each Part 11 control, and what FDA investigators look for.

April 20, 202612 min read

Electronic Signatures for CROs: What Contract Research Organizations Need for Part 11 Compliance

CROs are named as regulated entities in FDA's 2024 guidance. Here's what the non-repudiation letter and delegation log requirements mean for you.

April 13, 202613 min read

Clinical Trial Document Management: E-Signature Requirements for Sites and Sponsors

Managing clinical trial documents with e-signatures requires a framework that satisfies FDA 21 CFR Part 11, ICH E6(R3), and the October 2024 FDA final guidance. This guide covers the documents sites and sponsors must sign, delegation of authority log requirements, TMF retention obligations, and platform evaluation criteria.

April 10, 202615 min read

What Makes an E-Signature Platform FDA Compliant? The Complete Technical Checklist

Every e-signature vendor claims FDA compliance. This guide explains what Part 11 Subpart B and Subpart C actually require at the technical level -- hash-chained audit trails, authentication at signing, signature meaning, tamper-evident records, and validation documentation -- plus a 14-question checklist to run against any vendor. Updated June 2026: applicability assessment added as Step 1 of any FDA compliance evaluation.

April 10, 202614 min read

E-Signatures for Pharmaceutical QA: Batch Records, SOPs, and Deviation Reports

Batch record signatures, SOP approvals, deviation sign-off: what FDA 21 CFR Part 11 and Part 211 actually require for pharmaceutical QA electronic signatures.

GxP Electronic Signature Requirements: What GMP, GLP, and GCP Each Demand

GMP, GLP, and GCP all build on Part 11, but each adds its own e-signature obligations. Here is exactly where GCP, GLP, and GMP requirements diverge.

April 7, 202614 min read

21 CFR Part 11 Compliant Electronic Records: Subpart B Requirements Explained

Subpart B of FDA 21 CFR Part 11 defines the requirements for compliant electronic records, covering validation, audit trails, access controls, record retention, and signature-to-record linking. This guide explains each section of Subpart B, common FDA 483 failures, and what the 2024 clinical investigations guidance changed for cloud-based systems. Updated June 2026: Part 11 applicability assessment framework added -- which systems must meet Subpart B and why the determination must be documented.

April 6, 202612 min read

FDA Inspection Readiness: Audit Trail Requirements and the Pre-Inspection Checklist (2026)

What FDA investigators actually request during an audit trail review, the most common 483 findings, and a practical pre-inspection checklist for 2026.

April 4, 202613 min read

March 30, 202611 min read

Choosing the Best E-Signature for Clinical Trials: 8 Requirements

What makes an e-signature platform right for clinical trials? This guide covers the 8 specific requirements drawn from 21 CFR Part 11, the FDA's 2024 final guidance, ICH E6(R3), and EU CTR 536/2014 — including guest signing, delegation of authority logs, IQ/OQ validation docs, and 25-year retention.

March 30, 202612 min read

Electronic Signature Audit Trail Requirements: 21 CFR Part 11, Annex 11, and ALCOA+

What FDA, EU GMP Annex 11, and ALCOA+ actually require for e-signature audit trails, plus the most common 483 failures inspectors cite.

March 27, 202611 min read

ALCOA+ Audit Trail Software Requirements: Complete Life Sciences Guide (2026)

ALCOA+ compliant audit trail software needs 8 core technical requirements. Here's what to check, from timestamping to the Traceable principle.

March 27, 202612 min read

Best 21 CFR Part 11 Compliant E-Signature Software (2026): What Actually Matters

Most vendors claim 21 CFR Part 11 compliance. Few can prove it. Here are the 7 technical requirements that separate real compliance from marketing claims.

Part 11 Electronic Signatures: Requirements, Components, and Common Mistakes

A practical guide to 21 CFR Part 11 electronic signature requirements -- Subpart B and Subpart C explained, common compliance failures at clinical research sites, and what FDA inspectors look for in 2026.

March 23, 20269 min read

Data Privacy

Electronic Signatures and GDPR Compliance: Full Guide

E-signature workflows process personal data under GDPR. Here's what Article 6, DPA requirements, and data subject rights mean for your platform.

March 16, 20269 min read

FDA Warning Letters Are Up 73%. Is Your Audit Trail Ready?

FDA warning letters jumped 73% in H2 2025. Here's what clinical trial sponsors and CROs need to know about Part 11 audit trails before your next inspection.

March 16, 20268 min read

March 14, 202610 min read

ALCOA+ Data Integrity: 9 Principles for Life Sciences

ALCOA+ violations show up in most FDA data integrity warning letters. Here's what each of the 9 principles requires for electronic records and audit trails.

March 13, 202610 min read

Audit Trails in Regulated Industries: Complete Guide

Audit trails are now the most-cited category in FDA Part 11 483 observations -- and EU GMP Annex 11 Clause 9 is expanding what must be logged before the 2026 finalization window. This guide covers FDA 21 CFR Part 11 Section 11.10(e), Annex 11 Clause 9 scope expansion (exports and archival now loggable), hash chain verification, the audit trail review gap FDA inspectors now specifically target, and implementation best practices for pharma, biotech, and CROs.

March 12, 202611 min read

EU Clinical Trial Regulation 536/2014: Sponsor Guide

EU CTR 536/2014 governs every EU clinical trial since 2025. Learn CTIS submission, 25-year retention, e-signature rules, and 2026 enforcement checkpoints.

March 11, 202611 min read

DocuSign Part 11 Module vs Purpose-Built Compliance Platforms

DocuSign addresses FDA 21 CFR Part 11 through a paid add-on module. Purpose-built platforms embed compliance controls natively. This guide compares the two architectures across audit trails, 2FA, validation burden, total cost of ownership, and organizational fit for life sciences. Updated June 2026 with EU GMP Annex 11 Clause 3 supplier qualification implications for vendor selection.

March 11, 202612 min read

How to Validate an E-Signature System: IQ/OQ/PQ Under CSA

How to validate an e-signature system with IQ/OQ/PQ under FDA's CSA guidance, including risk-based testing, Part 11 mapping, and qualification checklists.

March 11, 202616 min read

E-Signature Vendor Evaluation Checklist: RFP Questions for Regulated Life Sciences

40+ RFP questions for evaluating e-signature vendors in pharma, biotech, and CROs. Covers FDA 21 CFR Part 11, EU GMP Annex 11, and ALCOA+ data integrity requirements with a weighted scoring template.

FDA Warning Letters & Data Integrity: Lessons from Real Enforcement Actions

Data integrity issues drive 60-80% of FDA GMP warning letters. See real citations: shared logins, missing audit trails, backdated records, and outcomes.

March 11, 202611 min read

Decentralized Clinical Trials & eConsent: E-Signature Requirements

Decentralized clinical trials (DCTs) use telehealth and direct-to-patient technologies for remote trial conduct. This guide covers the FDA's September 2024 DCT guidance, eConsent best practices, e-signature compliance under Part 11 and ICH E6(R3), and data integrity for remote workflows.

March 11, 202612 min read

How to Migrate to a Part 11 E-Signature Platform: 6-Phase Framework

Migrating to a Part 11 compliant e-signature platform takes structured change control. Here's the six-phase framework, from requirements to cutover.

Medical Device E-Signatures Under QMSR, ISO 13485 & EU MDR

The FDA's QMSR replaced the QSR on February 2, 2026, and the first QMSR inspection cycle is now underway. This guide covers how e-signatures interact with the new QMSR, Part 11's independent requirements, ISO 13485:2016 design controls and electronic records, EU MDR documentation obligations, and what medical device companies now face in their first QMSR implementation year -- including quality system changes that require re-validation of existing e-signature workflows.

AI & Electronic Signatures in Regulated Industries: Compliance Guide

AI is transforming e-signature workflows in life sciences — from intelligent document routing to anomaly detection and predictive compliance. This guide covers the FDA's AI guidance, EU AI Act high-risk classification, Part 11 implications, and a risk-based framework for adopting AI-enhanced compliance tools.

CSV vs CSA: Computer System Validation vs Software Assurance Explained

FDA's Computer Software Assurance guidance replaces traditional CSV with risk-based validation. Here's how the two approaches compare for e-signature systems.

EU GMP Annex 11 (2025 Draft): Computerized Systems Compliance Guide

EU GMP Annex 11's 2025 draft adds MFA at signing, wider audit trail scope, and new batch release documentation rules. Here is what changes and why.

March 10, 202611 min read

How to Choose an E-Signature Platform for Life Sciences

Evaluating e-signature platforms for pharma, biotech, and medical devices? This guide covers FDA 21 CFR Part 11 compliance, audit trail capabilities, 2FA requirements, validation documentation, red flags to avoid, and total cost of ownership for regulated industries. Updated June 2026: new section on EU GMP Annex 11 Clause 3 supplier qualification as a required vendor selection criterion for GMP-regulated organizations.

Healthcare

HIPAA-Compliant Electronic Signatures: Requirements Guide

HIPAA allows e-signatures on PHI, but only with a BAA, AES-256 encryption, audit controls, and MFA in place. Here is what the Security Rule actually requires.

March 6, 20269 min read

eIDAS vs ESIGN Act: Complete Comparison Guide (2026)

eIDAS 2.0 is expanding qualified trust services while the ESIGN Act stays technology-neutral. This guide compares the two frameworks on legal validity, signature tiers (SES/AES/QES), cross-border recognition, a 7-row document-type tier decision table for life sciences, June 2026 EU Digital Identity Wallet pilot implications for clinical trial sites, and what multinational regulated organizations must do to satisfy both.

March 3, 20269 min read

February 28, 202610 min read

GxP Compliance for Electronic Records: GLP, GMP, GCP Guide

What GxP compliance actually requires for electronic records under GMP, GLP, GCP, and EU Annex 11, with ALCOA+ principles and validation basics explained.

February 25, 202614 min read

Electronic Signatures in Clinical Trials: 2024 FDA Guidance Update

FDA's 2024 guidance clarified e-signature rules for clinical trials: non-repudiation letters, hybrid records, cloud systems, risk-based validation.